ONO ex­er­cis­es Fate CAR-T op­tion in lat­est twist to part­ner­s' four-year deal

While some of the biggest play­ers have jumped on CAR-T ther­a­pies and their po­ten­tial in med­i­cine, one of the newest de­vel­op­ments in the space in­volves two small­er play­ers.

Im­munother­a­py and on­col­o­gy play­er Fate Ther­a­peu­tics put out word Mon­day that col­lab­o­ra­tor ONO Phar­ma­ceu­ti­cal is ex­er­cis­ing its op­tion for HER2-tar­get­ing CAR-T cell ther­a­py called FT825/ONO-8250. The op­tion for the pre­clin­i­cal can­di­date, ac­cord­ing to the biotechs, is that the pair will joint­ly de­vel­op and com­mer­cial­ize the drug for the US and Eu­rope, and ONO will main­tain ex­clu­sive de­vel­op­ment and com­mer­cial­iza­tion rights for the rest of the world.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER